NCT07061964 2026-03-19
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
8 trialsNCT03775265 2026-03-18
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04164082 2026-03-18
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07000084 2026-03-04
GAIN-BCG
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05521698 2026-02-17
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Not yet recruiting
NCT02621151 2025-10-07
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NYU Langone Health
Phase 2 Active not recruiting
NCT06537154 2025-07-30
NEO-BLAST
University of British Columbia
Phase 2/3 Recruiting
NCT07067749 2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3 Recruiting